52
Participants
Start Date
August 5, 2019
Primary Completion Date
April 9, 2025
Study Completion Date
May 31, 2026
AZD6738
MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
Washington University, St Louis
BIDMC, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital Cancer Center, Boston
Collaborators (1)
AstraZeneca
INDUSTRY
Massachusetts General Hospital
OTHER